← FDA DRUG APPROVALS
FDA ANDA · ANDA202912
ABACAVIR, LAMIVUDINE AND ZIDOVUDINE
abacavir , lamivudine and zidovudine
Sponsor: LUPIN
APPLICATION
ANDA202912
TYPE
ANDA
ORIGINAL APPROVAL
2013-12-05
LATEST ACTION
2022-04-06
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINEDiscontinued
ABACAVIR SULFATE EQ 300MG BASE, LAMIVUDINE 150MG, ZIDOVUDINE 300MG · TABLET · ORAL
Approval history
2022-04-06Labeling · Supplement 13 · standardAP
2020-12-22Labeling · Supplement 7 · standardAP
2020-12-22Labeling · Supplement 5 · standardAP
2020-12-22Labeling · Supplement 12 · standardAP
2020-12-22Labeling · Supplement 10 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.